Core Viewpoint - Danuo Pharmaceutical, a biotech company based in Suzhou, is on the verge of submitting a new drug application for the world's first and only new molecular entity candidate for treating Helicobacter pylori infection, marking a significant milestone in the field of antibiotic development [5][10][14]. Company Overview - Founded in 2013 by Ma Zhenkun, Danuo Pharmaceutical focuses on developing treatments for bacterial infections and related diseases, with a strong emphasis on Helicobacter pylori [8][9]. - The company has a pipeline of seven drugs in development, including "Rifotnizole," which has successfully completed Phase III clinical trials [10][13]. Investment and Financials - Danuo Pharmaceutical has successfully raised funds through multiple financing rounds, reaching a valuation of over 2 billion yuan after its E round [15][17]. - The company has accumulated a net loss of 192 million yuan in 2023, which decreased to 146 million yuan in 2024, indicating a positive trend in financial performance [14]. Market Potential - The global market for antibacterial drugs is projected to grow from $45.5 billion in 2024 to $60.3 billion by 2029, with the market for Helicobacter pylori treatments expected to increase from $6.9 billion to $10 billion in the same period [14]. Strategic Partnerships - Danuo has established a commercial partnership with Yuan Da Life Science Group for the marketing and distribution of "Rifotnizole," which includes a payment agreement potentially worth up to 775 million yuan [14][17]. Future Outlook - The company plans to submit the new drug application for "Rifotnizole" by the end of August 2025 and aims to establish a drug production and R&D base in Zhongshan, Guangdong [17][18].